Nasus Pharma Ltd. (NSRX) Stock

Nasus Pharma Ltd. (NSRX) is a Healthcare stock trading at $3.11 (as of 2026-06-18), with a market capitalization of $49.35M and a trailing P/E of -4.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company developing intranasal drug products aimed at emergency medical conditions, including severe allergies, anaphylaxis, and opioid overdose. Its pipeline includes intranasal powder formulations such as NS002 (epinephrine) and NS001 (naloxone) for acute treatment.

Valuation — source: SEC EDGAR (first-party)
Price	$3.11
Market Cap	$49.35M
P/E Ratio	-4.7
Price / Book	10.94
Price / Sales	0.02
DCF Value (model)	$-9.17
DCF Upside vs Price	-394.9%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$1.24B
Net Margin	-0.5%
Return on Equity	-211.6%
Current Ratio	2.24

Financial Health — source: SEC EDGAR
Altman Z-Score	246.56 (safe)

Valuation vs Sector & Industry
Stock P/E	-4.7
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-122.3%
vs Industry	-127.4%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Balyasny Asset Management L.P. ($1.99M)
Institutional Holders Tracked	9

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Dan Teleman
Employees	2
Country	IL
IPO Date	2025-08-13

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.